Gelonghui, May 31, 丨 Liankang Biotechnology Group (00690.HK) issued an announcement. On May 31, 2024, the lender (Beijing Bokangjian Gene Technology Co., Ltd., an indirect wholly-owned subsidiary of the company) signed a loan agreement with the borrower (i.e. Guangzhou Taili Biomedical Technology Co., Ltd.). Based on this, the lender agreed to provide the borrower with a principal amount of RMB 5.8 million for a period of 16 months from June 1, 2024 to facilitate the borrower's R&D and operation.
联康生物科技集团(00690.HK)拟向广州太力生物医药科技提供本金额580万元贷款
Liankang Biotechnology Group (00690.HK) plans to provide Guangzhou Taili Biomedical Technology with a capital loan of 5.8 million yuan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.